Phase 1 Evaluation of TERN-701 Safety, Tolerability, Pharmacokinetics, and Efficacy in Chronic Myeloid Leukemia Patients

The primary objective of this Phase 1 clinical trial is to evaluate the **safety**, **tolerability**, **pharmacokinetics**, and **efficacy** of TERN-701 in participants with **Chronic Myeloid Leukemia**. This study is clinically relevant as it aims to assess the potential of TERN-701 as a therapeutic option for this hematological malignancy, which could lead to improved treatment outcomes and patient management. No secondary objectives are provided for this trial.

The clinical trial involves a total of **59 participants** diagnosed with **Chronic Myeloid Leukemia**. The study population includes both male and female subjects, with an age range categorized under code "3", which typically represents adults. Participants were selected to include a vulnerable population, although specific criteria for vulnerability are not detailed. The trial does not specify particular lifestyle considerations such as diet or physical activity. The selection process and any additional inclusion or exclusion criteria have not been provided by the sponsor.

The clinical trial is designed to evaluate the **safety**, tolerability, pharmacokinetics, and efficacy of TERN-701 in participants diagnosed with **Chronic Myeloid Leukemia**. This study is structured as a Phase 3, randomized, double-blind, controlled trial. The estimated recruitment start date is April 4, 2024, with an anticipated end date of March 26, 2027. The trial will involve multiple study visits, beginning with an inclusion visit, also known as the screening visit, where participants will be assessed for eligibility based on predefined criteria. Following successful screening, participants will be randomized to receive either the investigational product or a control. The trial will include several follow-up visits to monitor participants' responses to the treatment and to assess any adverse events. These visits are crucial for collecting data on the primary and secondary endpoints of the study. The end-of-study visit will mark the conclusion of the participant's involvement, where final assessments will be conducted to evaluate the overall outcomes of the treatment. The expected length of participant involvement will span the duration of the trial, from the initial screening to the end-of-study visit. Participants may be subject to early termination from the study if they experience significant adverse effects, fail to comply with the study protocol, or withdraw consent. The trial aims to provide comprehensive data on the investigational product's impact on **Chronic Myeloid Leukemia**, contributing to the understanding and potential treatment options for this condition.

The clinical trial involves the administration of an **experimental medication**. However, specific details regarding the name, pharmaceutical form, dosage, route, and frequency of administration are not provided in the available data. The trial documentation does not specify whether the medication is a **paediatric formulation** or if it is classified as an **orphan drug**. Additionally, there is no information on the maximum daily dose, total dose, or treatment period for the experimental medication.

In addition to the experimental medication, the trial may include the use of **non-experimental treatments** such as standard-of-care therapy, placebo, or comparator treatments. However, the data does not provide explicit details about these treatments. Information regarding the administration, dosing schedules, and participant compliance monitoring for these non-experimental treatments is also not available.

The clinical trial is designed to assess efficacy in a Phase 3 study. The trial is scheduled to commence recruitment on April 4, 2024, with an estimated completion date of March 26, 2027. The efficacy of the intervention will be evaluated using specific parameters or endpoints, although these are not detailed in the provided data. The trial will follow a structured methodology to measure, collect, and analyze these efficacy parameters at predetermined timepoints throughout the study duration. The trial's design and execution will adhere to rigorous scientific standards to ensure the reliability and validity of the efficacy assessments.